Outsourcing

SGD Pharma and Prince launch sterile Type I glass nasal vials for the US market, targeting complex chronic conditions like Alzheimer's and Parkinson's.

The two companies have entered into a licensing agreement to commercialize biosimilars in Latin America.

The companies have extended a commercial supply partnership for the manufacture of Sohonos (palovarotene), which is a treatment for the ultra-rare disease, fibrodysplasia ossificans progressiva.

Trust-based CDMO partnerships are becoming essential to accelerate injectable drug development, manage risk, and ensure resilient biopharma supply.

Innovators are increasingly focused on whether outsourced partners can help them make better decisions earlier, before uncertainty becomes late-stage risk.

Industry experts discuss the benefits of utilizing contract development and contract research organizations in drug discovery and development.

Eli Lilly & CSL seal a deal for clazakizumab partitions rights to maximize lifecycle value. CSL retains ESKD focus as Lilly prioritizes commercialization.

Integrated CDMO networks streamline complex drug development across advanced modalities like ADCs.

PharmTech spoke with Katy MacLellan, Technical Team leader, Symbiosis Pharmaceutical Services Ltd., about the women in the pharmaceutical industry that inspire her.

Cellares raises $257M to scale its automated manufacturing model and validate a move toward becoming an integrated development and manufacturing organization, or IDMO.

Repertoire’s T cell receptor-epitope discovery platform will be used to develop tolerizing therapy development candidates with Eli Lilly and Company.

Contract development and manufacturing organizations offer specialized services to help sponsor companies develop drug products that better serve the unique needs of patients.

The company is adding a second production line at its Etten-Leur facility in The Netherlands to meet customer needs.

The CRDMO’s new facility will double chemistry capacity for drug discovery research and scale-up projects.

Chromatin Bioscience, Mediphage Bioceuticals, and Entos Pharmaceuticals will receive advisory services and funding from UKRI Innovate UK and Canada’s NRC IRAP to develop next-generation genetic medicines.

FUJIFILM Irvine Scientific has changed its name to FUJIFILM Biosciences to better align with the company’s work in cell culture media manufacturing.

The collaboration will initially focus on advanced stages of solid cancers such as colorectal, pancreatic, lung, and breast, but may expand to other cancer types in the future.

Luca Cavazzini, Sales & Marketing Director at IMA Active, discusses some of the industry’s most common manufacturing challenges, such as sustainability, continuous processes, and technology advancements.

A worldwide, exclusive license is being granted to develop and commercialize enzyme replacement therapies using proprietary platform technology.

Christian Dowdeswell, managing director, Arcinova, a Quotient Sciences company, discusses what makes a CDMO that offers end-to-end service beneficial.

ACG showcased the expansion of its European presence, and Bora Pharmaceuticals participates in a discussion about CDMO innovation.

SK pharmteco boosts US peptide synthesis and purification capabilities, advancing reliable large-scale manufacturing for biopharma innovation.

The company will also highlight its sustainability strategies and quality solutions at the event.

Pharmaceutical Technology® spoke with Juliana Maynard, PhD, Head of Translational Imaging at Medicines Discovery Catapult, to find out what makes radiopharmaceuticals unique and how MDC’s collaboration with Crown Bioscience can help developers of these treatments for cancer.

Sept. 30 marked 61 days since July 31, one day past the timeframe President Donald Trump had set forth for companies to lower prescription drug prices in the United States.